New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymosin Alpha-1 vs PNC-27

Thymosin Alpha-1 vs PNC-27

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1
Immune Support
PNC-27
Summary
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
Half-Life
2–3 hours
Not well established; estimated minutes to hours
Admin Route
SubQ
Intravenous (research), Intraperitoneal (research)
Research
Typical Dose
0.8–1.6 mg
Not established for humans; research doses vary by cell line and model
Frequency
Twice weekly
Not established for human use
Key Benefits
  • Enhances T-cell and NK cell activity
  • Supports recovery from viral and bacterial infections
  • May reduce inflammation systemically
  • Supports healthy aging and immune resilience
  • Improves vaccine response
  • Supports liver health
  • May help with chronic fatigue syndrome and post-viral conditions
  • Approved in multiple countries for hepatitis B and C treatment
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
Side Effects
  • Injection site irritation
  • Mild flu-like symptoms initially (immune activation)
  • Fatigue (rare)
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
Stacks With